A sensitive exosome-based biosignature for the diagnosis of prostate cancer.
Christine Kuslich(Phoenix (United States)), David Spetzler(Caris Life Sciences (United States)), J. Kim, Traci Pawlowski(Illumina (United States)), Tingming Deng, Teresa L. Tinder(Freeport-McMoRan (United States)), J. C. Kimbrough(Freeport-McMoRan (United States))
Cited by 0
Related Papers
Changes in circulating microRNA levels associated with prostate cancer
|British Journal of Cancer|2012|717
Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy
|Cancer Cell|2021|453
Identification of genetic variants using bar-coded multiplexed sequencing
|Nature Methods|2008|305